JP2004509871A - 二重ヒスタミンｈ１およびｈ３のアゴニストまたはアンタゴニストとしての置換イミダゾール - Google Patents

二重ヒスタミンｈ１およびｈ３のアゴニストまたはアンタゴニストとしての置換イミダゾール Download PDF

Info

Publication number
JP2004509871A
JP2004509871A JP2002529071A JP2002529071A JP2004509871A JP 2004509871 A JP2004509871 A JP 2004509871A JP 2002529071 A JP2002529071 A JP 2002529071A JP 2002529071 A JP2002529071 A JP 2002529071A JP 2004509871 A JP2004509871 A JP 2004509871A
Authority
JP
Japan
Prior art keywords
compound
compounds
mmol
added
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002529071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509871A5 (enExample
Inventor
シー，　ネン−ヤン
ソロモン，　ダニエル　エム．
ピウィンスキ，　ジョン　ジェイ．
ルポ，　アンドリュー　ティー．　ジュニア
グリーン，　マイケル　ジェイ．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2004509871A publication Critical patent/JP2004509871A/ja
Publication of JP2004509871A5 publication Critical patent/JP2004509871A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002529071A 2000-09-20 2001-09-18 二重ヒスタミンｈ１およびｈ３のアゴニストまたはアンタゴニストとしての置換イミダゾール Withdrawn JP2004509871A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23405300P 2000-09-20 2000-09-20
PCT/US2001/029095 WO2002024659A2 (en) 2000-09-20 2001-09-18 Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists

Publications (2)

Publication Number Publication Date
JP2004509871A true JP2004509871A (ja) 2004-04-02
JP2004509871A5 JP2004509871A5 (enExample) 2008-09-11

Family

ID=22879692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002529071A Withdrawn JP2004509871A (ja) 2000-09-20 2001-09-18 二重ヒスタミンｈ１およびｈ３のアゴニストまたはアンタゴニストとしての置換イミダゾール

Country Status (15)

Country Link
US (1) US6506756B2 (enExample)
EP (1) EP1318994B1 (enExample)
JP (1) JP2004509871A (enExample)
CN (1) CN1461303A (enExample)
AR (1) AR030946A1 (enExample)
AT (1) ATE387439T1 (enExample)
AU (1) AU2001292730A1 (enExample)
CA (1) CA2421826C (enExample)
DE (1) DE60133014T2 (enExample)
ES (1) ES2300364T3 (enExample)
HK (1) HK1052179A1 (enExample)
MX (1) MXPA03002448A (enExample)
MY (1) MY117975A (enExample)
TW (1) TW589303B (enExample)
WO (1) WO2002024659A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529161A (ja) * 2002-04-18 2005-09-29 シェーリング　コーポレイション ヒスタミンｈ３アンタゴニストとしての１−（４−ピペリジニル）ベンズイミダゾロン

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607862B2 (en) 2001-08-24 2003-08-19 Intel Corporation Damascene extreme ultraviolet lithography alternative phase shift photomask and method of making
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
EP1499316B1 (en) * 2002-04-18 2008-03-19 Schering Corporation (1-4-piperidinyl)benzimidazole derivatives useful as histamine h3 antagonists
NL1026634C2 (nl) * 2004-07-12 2006-01-16 Willem Jacob Van Der Burg Psychofarmaceutisch preparaat en werkzame stof daarin.
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US9224955B1 (en) * 2014-10-31 2015-12-29 Feng-wen Yen Purifying method for organic optoelectronic material
CN113880808B (zh) * 2020-07-03 2024-12-31 合肥医工医药股份有限公司 一类三唑类化合物、制备方法及其医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
ZA893104B (en) * 1988-04-28 1989-12-27 Schering Corp Novel benzopyrido piperidine,piperidylidene and piperazine compounds,compositions,methods of manufacture and methods of use
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
DK0448765T3 (da) 1990-03-30 1994-09-19 Heumann Pharma Gmbh & Co Anvendelse af guanidinderivater til fremstilling af et lægemiddel med NPY-antagonistisk virkning
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
WO1993012093A1 (en) 1991-12-18 1993-06-24 Schering Corporation Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine h3 agonists/antagonists
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
NZ330898A (en) 1993-11-15 2000-01-28 Schering Corp Phenyl-alkyl imidazoles as H3-receptor antagonists in particular for the treatment of inflammation
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
PT1019050E (pt) 1997-06-24 2002-09-30 Novo Nordisk As Utilizacao de agonisticos e de antagonisticos de somatostatina para o tratamento de doencas associadas ao olho
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
AU4387699A (en) 1998-07-24 2000-02-14 Russinsky Limited A process for preparing benzocycloheptapyridin-11-ones

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529161A (ja) * 2002-04-18 2005-09-29 シェーリング　コーポレイション ヒスタミンｈ３アンタゴニストとしての１−（４−ピペリジニル）ベンズイミダゾロン
JP2006206603A (ja) * 2002-04-18 2006-08-10 Schering Plough Corp ヒスタミンｈ３アンタゴニストとしての１−（４−ピペリジニル）ベンズイミダゾロン

Also Published As

Publication number Publication date
DE60133014D1 (de) 2008-04-10
CA2421826A1 (en) 2002-03-28
HK1052179A1 (zh) 2003-09-05
EP1318994A2 (en) 2003-06-18
CN1461303A (zh) 2003-12-10
ATE387439T1 (de) 2008-03-15
US6506756B2 (en) 2003-01-14
CA2421826C (en) 2009-10-27
ES2300364T3 (es) 2008-06-16
DE60133014T2 (de) 2009-02-26
MY117975A (en) 2004-08-30
AR030946A1 (es) 2003-09-03
AU2001292730A1 (en) 2002-04-02
MXPA03002448A (es) 2003-06-19
WO2002024659A2 (en) 2002-03-28
EP1318994B1 (en) 2008-02-27
US20020086859A1 (en) 2002-07-04
WO2002024659A3 (en) 2002-10-24
TW589303B (en) 2004-06-01

Similar Documents

Publication Publication Date Title
JP4211394B2 (ja) プロパン−１，３−ジオン誘導体
JP4563800B2 (ja) ヒスタミンｈ３アンタゴニストとしての１−（４−ピペリジニル）ベンズイミダゾロン
JP2001518895A (ja) ソマトスタチン作働薬
CZ127299A3 (cs) 1-Fenyl-benzimidazolové sloučeniny a jejich použití jako modulátorů GABAA receptorů
CZ20033437A3 (cs) N-Aroylové cyklické aminové deriváty jako antagonisté orexinového receptoru
JP2002539121A (ja) ヒスタミンｈ３リガンドとしてのイミダゾール化合物
WO1994007891A1 (en) 1-substituted oxindoles and azaoxindoles as novel cognition enhancers
US6762186B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
US6506756B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
US6528522B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
US6518287B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
US6159941A (en) Use of somatostatin agonists and antagonists for treating diseases related to the eye
US5665726A (en) Benzo[5,6]cycloheptapyridines, compositions and methods of use
US5519132A (en) Pyridine compounds
HK1003883A1 (en) Indole derivatives as 5-ht receptor antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080714

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20101221